Myopia Day - Session 3 - Webinar: 0.01% atropine for myopia control – from evidence to everyday practice

Optometry Today (OT), in partnership with the AOP and headline sponsor CooperVision, is pleased to present a full day of myopia-focused education.

This event features a series of online sessions delivered by national and international experts, offering valuable insights into the contemporary clinical management of myopia.

The programme includes six webinars, each providing one interactive CPD point. Attendees will have the opportunity to learn from leading experts in the field, build confidence in managing myopia and exchange knowledge with peers. Delegates may attend the full programme or choose individual sessions that best match their clinical interests.

Please note: You will not be eligible for CPD if you dial in to audio only using a phone.

Session 1: Spex, drugs or contact lenses – choosing the best intervention for controlling myopia in children - Book below
Session 2: Eyes on the future – what's new in myopia management - Book below
Session 3: 0.01% atropine for myopia control – from evidence to everyday practice - Book now
Session 4: How to identify and manage a pre-myope - Book below
Session 5: Beyond spectacles – real-world insights and three-year evidence in paediatric myopia control - Book below
Session 6: Make your impact – embracing orthokeratology in practice - Book below

Session 3: 0.01% atropine for myopia control – from evidence to everyday practice

This CPD session will provide an overview of childhood myopia management, beginning with a brief reminder of why addressing the condition early is important in reducing the lifetime risk of ocular disease and visual impairment. It will explore effective ways of communicating these risks to patients and their families, supporting informed decision-making and engagement with management strategies. 

The session will then focus on identifying children at risk of myopia progression, alongside a review of the key clinical tests used in assessment and monitoring. A central component will be the use of low-concentration atropine for managing progressive myopia in children, including its mechanism of action, the current clinical evidence supporting its efficacy, potential side effects and approaches to managing rebound. Practical considerations will also be covered, with specific reference to its licensed use in the UK. 

Finally, the session will look ahead to improving access to myopia management, exploring potential future NHS pathways and what these developments could mean for optometry practice and the wider profession. Particular emphasis will be placed on equity of access and why it is a critical consideration in delivering effective, inclusive eye care.

Learning outcomes

• Practitioners will be able to explain the risks of childhood myopia progression to support informed decision-making by children and their parents or carers, relative to their scope of practice (s.2)
• Practitioners will be able to recognise issues around access to myopia management and the potential for inclusive service provision within evolving NHS pathways (s.13).